RHEL (RHEL) News
Follow RHEL (RHEL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Toronto, Ontario--(. - September 29, 2026) - Rhelion Life Sciences Corp. CSE:RHEL (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal ps
NEWS | Sep 29, 2026, 11:58 AM UTC
M
Rhelion ships PEX010 for Phase 3 microdose psilocybin trial
Filament delivered PEX010 to Bruyère Health Research Institute for a Phase 3, placebo-controlled microdose psilocybin trial in palliative care across seven Canadian sites.
EQUITY | Sep 21, 2026, 11:51 AM UTC
L
Rhelion subsidiary Filament Health signs CHDR PEX010 supply deal
Filament Health signed a supply and licensing agreement with CHDR to provide PEX010 (1 mg and 5 mg) and placebos for a psilocybin study, with regulatory support; the study requires regulatory and ethics approval.
EQUITY | Sep 17, 2026, 12:01 PM UTC
L
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Toronto, Ontario--(. - September 10, 2026) - Rhelion Life Sciences Corp. CSE:RHEL (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal p
EQUITY | Sep 10, 2026, 12:01 PM UTC
L
Filament Health ships PEX010 to Australia for University of Melbourne trial
Rhelion Life Sciences says its wholly owned subsidiary Filament Health completed shipment of PEX010 to Australia for a University of Melbourne trial of psilocybin-assisted physiotherapy in functional neurological disorde
EQUITY | Sep 08, 2026, 11:56 AM UTC
L
Rhelion confirms further PEX010 delivery to Germany compassionate use program
Rhelion Life Sciences said it has confirmed further delivery of Filament Health's PEX010 to Germany’s First Psilocybin Compassionate Use Program.
EQUITY | Sep 03, 2026, 11:46 AM UTC
L
Filament Health gets new US patent in natural psilocybin estate
Rhelion Life Sciences’ wholly owned subsidiary Filament Health issued a new United States patent, extending its natural psilocybin patent estate.
EQUITY | Aug 27, 2026, 12:26 PM UTC